We also observed a reduced proportion of p-p38-positive CD34+ myeloblasts in AML compared to normal settings, but statistical significance was only attained for non-M4/M5 AML (non-M4/M5 AML vs. NBM: 48% vs. 83.6%, p = 0.0166; AML M4/M5 vs. NBM: 33.7% vs. 83.6%, p = 0.0732) (Figure 6A). Here, CD34 is linked to acute myeloid leukemia.